Gilde Healthcare leads USD 20 million financing round of Belgian sleep therapy company Nyxoah - Gilde Healthcare

Gilde Healthcare leads USD 20 million financing round of Belgian sleep therapy company Nyxoah

July 7, 2016

Board will be strengthened with industry experts and Enrique Vega appointed as new CEO

Mont-Saint-Guibert, Belgium – Nyxoah S.A., a medical device company focused on developing a neurostimulation based, disruptive therapy for patients suffering from Obstructive Sleep Apnea (OSA), announced today it has raised €18 million ($20 million) in fresh capital. The financing was led by Gilde Healthcare. SRIW and all existing shareholders also participated in the round. The proceeds will be used to finance Nyxoah’s go-to-market strategy, including CE Mark approval and the US FDA approval process.

The company is pleased to announce the appointment of Enrique Vega as Chief Executive Officer as of September 1st 2016. Mr. Vega is an experienced senior executive with a successful track record in the Cardiac Rhythm Management, Sleep Apnea and Neurostimulation fields. Nyxoah’s board is now composed of:

  • Robert Taub (company co-founder) – Chairman,
  • Janke Dittmer (Partner at Gilde Healthcare) – Vice-Chairman,
  • Jürgen Hambrecht (former CEO of BASF) – Director,
  • Don Deyo (former VP Neuromodulation R&D at Medtronic) – Independent Director and
  • Kevin Rakin (experienced lifescience executive and investor) – Independent Director.

“In Western countries alone there are 5 million OSA patients who require treatment but have failed current gold standard therapy,” said Robert Taub, Nyxoah co-founder and CEO “this large unmet need can be addressed by Nyxoah’s bilateral neurostimulation therapy.”

 

About Nyxoah

Nyxoah S.A. is a medical device company, focused on developing and commercializing a disruptive neurostimulation based therapy for the treatment of Obstructive Sleep Apnea (OSA). Headquartered in Mont-Saint-Guibert, Nyxoah SA was co-founded in 2009 by Robert Taub.

The company has developed the first and only lead-free neurostimulator, capable of delivering bilateral hypoglossal nerve stimulation for moderate to severe OSA patients, who have failed conventional CPAP therapy.

About Gilde Healthcare

Gilde Healthcare (Utrecht, The Netherlands and Cambridge, USA) is a European specialist investment firm focused on private healthcare companies. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, medical devices, therapeutics and healthcare services. Gilde successfully builds healthcare businesses across Europe and US, investing up to €30 million in a single portfolio company. For a list of Gilde’s portfolio companies please visit the website at www.gildehealthcare.com.

Gilde Healthcare raises €600 million to invest in healthcare innovation

A balanced mix of international investors commits €600 million to Gilde Healthcare Venture&Growth VI, a transatlantic investment fund Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by its...
April 19, 2023

Gilde Healthcare portfolio company Moximed obtains FDA Market Authorization of the MISHA™ Knee System for People Suffering from Knee Osteoarthritis

Implantable shock absorber (ISA) relieves pain and improves function in people ineligible for, or unwilling to undergo, joint replacement MISHA Knee System is implanted during an outpatient procedure; it's the first and only device of...
April 13, 2023

Gilde Healthcare company Adcendo announces extension of series A financing to EUR 82M to develop its first-in-class ADC pipeline

Gilde Healthcare portfolio company Adcendo Aps (‘Adcendo’), focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, today announces the successful completion of a Series...
April 4, 2023